SRC and metastatic neoplasm: Antibodies or small molecule inhibitors that target both EGFR and TGF-β pathways given together with a src inhibitor could also be used even when metastatic disease is present, perhaps followed by the addition of chemotherapeutic agents such as gemcitabine.